ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Claritas Rx Access Analytics Delivers Real-Time Visibility Into Biopharma Brand Performance

Real-Time Channel Intelligence Empowers Smarter Market Access and Better Patient Outcomes

New Thought Leadership Entitled “One Month to $241K: Real-Time Market Access Insights Deliver Measurable Gains” Now Available

Claritas Rx, the patient journey experts, announced the availability of Access Analytics that delivers real-time channel and competitive visibility into brand performance by reducing the data lags that plague traditional reporting methods. Access Analytics equips Market Access teams with transparency across the treatment continuum, enabling them to respond swiftly and efficiently to emerging needs, evaluate program effectiveness and optimize patient services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908890658/en/

“You can’t solve what you can’t see. Without real-time insights, barriers to treatment go unnoticed, patients face delays, and brand performance suffers. Claritas Rx Access Analytics changes that—delivering real-time, intuitive dashboards that provide comprehensive channel, payer, and patient visibility into critical metrics like enrollments, conversion rates, time-to-fill, persistence, and more,” said Michael Fitzgibbons, CEO of Claritas Rx. “By enabling teams to address barriers sooner, Access Analytics drives significant financial value for organizations and allows more patients to start and maintain much-needed therapies, delivering measurable improvements to both patient care and business performance.”

“You can’t solve what you can’t see. Without real-time insights, barriers to treatment go unnoticed, patients face delays, and brand performance suffers. Claritas Rx Access Analytics changes that—delivering real-time, intuitive dashboards that provide comprehensive channel, payer, and patient visibility into critical metrics like enrollments, conversion rates, time-to-fill, persistence, and more,” said Michael Fitzgibbons, CEO of Claritas Rx. “By enabling teams to address barriers sooner, Access Analytics drives significant financial value for organizations and allows more patients to start and maintain much-needed therapies, delivering measurable improvements to both patient care and business performance.”

Market Access teams face significant challenges due to a lack of timely, unified and actionable data. Fragmented information from specialty pharmacies, support hubs and payers result in therapy initiation delays, missed opportunities to optimize contracts and workflows and an increased risk of patient drop-offs. Relying on manual processes and disjointed tracking tools, such as spreadsheets or navigating multiple systems, not only wastes valuable time but also impedes proactive decision-making, partner communication and engagement, and strategic planning. These inefficiencies are compounded as critical information is easily overlooked, making it harder for organizations to deliver optimal patient care and maximize operational performance.

By unifying complex data into intuitive dashboards, Claritas Rx Access Analytics enables:

  • Identification of barriers
  • Recognition of trends
  • Comparison of partner performance
  • Refinement of access strategies

“You can’t solve what you can’t see. Without real-time insights, barriers to treatment go unnoticed, patients face delays, and brand performance suffers. Claritas Rx Access Analytics changes that—delivering real-time, intuitive dashboards that provide comprehensive channel, payer, and patient visibility into critical metrics like enrollments, conversion rates, time-to-fill, persistence, and more,” said Michael Fitzgibbons, CEO of Claritas Rx. “By enabling teams to address barriers sooner, Access Analytics drives significant financial value for organizations and allows more patients to start and maintain much-needed therapies, delivering measurable improvements to both patient care and business performance.”

Access Analytics Compliance

Claritas Rx Access Analytics upholds the highest standards in healthcare data protection, including HIPPA, HITECH, GDPR, and SOC 2. Claritas Rx understands regulatory expectations and protects patients at every step.

Thought Leadership: “One Month to $241K: Real-Time Market Access Insights Deliver Measurable Gains”

Accelerating market access data delivery from multi-day lags to next-day reporting enables earlier patient interventions, reduces therapy abandonment, and can potentially deliver over $241K in measurable revenue gains in one month. A single-day improvement in data availability supported faster therapy starts for hundreds of patients, prevented drop-offs, and freed teams to focus on strategic initiatives — boosting agility, strengthening collaboration and improving patient outcomes.

Claritas Rx’s new white paper entitled “One Month to $241K: Real-Time Market Access Insights Deliver Measurable Gains” is now available for Market Access executives to download.

A webinar on this topic will be held on September 25th at 1pm ET. The 30-minute session is tailored for biopharma access and patient support leaders and will focus on how real-time, integrated data can overcome operational barriers, accelerate therapy initiation, reduce patient abandonment and drive measurable revenue growth. Market Access executives can register here.

Media can contact Emily Brennan, EBrennan@ClaritasRx.com, to register for the webinar and receive a copy of the white paper.

About Claritas Rx

Based in South San Francisco, CA, Claritas Rx helps rare disease and specialty brands remove the barriers that keep patients from accessing and staying on the treatments they need. By uniting the most complete view of the patient journey with purpose-built technologies, we predict and resolve access challenges before they disrupt care. Our intelligent solutions combine advanced analytics, real-world data, AI, and in-line CRM capabilities to increase start and refill rates, reduce abandonment, and improve brand performance. For more information, visit www.ClaritasRx.com.

Access Analytics equips Market Access teams with transparency across the treatment continuum, enabling them to respond swiftly and efficiently to emerging needs, evaluate program effectiveness and optimize patient services.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.00
+2.08 (1.00%)
AAPL  264.18
-8.77 (-3.21%)
AMD  200.21
-3.47 (-1.70%)
BAC  49.83
-2.47 (-4.72%)
GOOG  311.43
+4.28 (1.39%)
META  648.18
-8.83 (-1.34%)
MSFT  392.74
-8.98 (-2.24%)
NVDA  177.10
-7.79 (-4.21%)
ORCL  145.40
-4.91 (-3.27%)
TSLA  402.51
-6.07 (-1.49%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.